If this formulation can increase, or at least preserve, the level of the different mucin subtypes in the excluded inflamed mucosa, this would be initial evidence of that the combination of the two substances may be beneficial for the treatment or prevention of DC. The gene discussed is MUC5AC; the disease is dyskeratosis congenita.